| Document |
Document Title |
|
WO/2024/153225A1 |
The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directe...
|
|
WO/2024/154147A1 |
The present invention provides an industrial process for the synthesis of Theacrine with high purity and quality.
|
|
WO/2024/153161A1 |
The present disclosure relates to substituted aminopyrimidine macrocyclic compounds, a preparation method therefor, and the medical uses thereof. Particularly, the present disclosure relates to substituted aminopyrimidine macrocyclic com...
|
|
WO/2024/152973A1 |
Provided in the present invention is a compound as a PRMT5-MTA inhibitor, which is a compound as represented by formula (I) or a pharmaceutically acceptable salt, an isotopic variant, a tautomer or a stereoisomer thereof. Further provide...
|
|
WO/2024/153067A1 |
Disclosed is a heterocycle-substituted five- and six-membered heteroaryl derivative, the structure of which is shown in formula (I). In addition, also disclosed are a pharmaceutically acceptable salt of the derivative, a stereoisomer the...
|
|
WO/2024/149269A1 |
The present invention relates to the field of chemical medicines, and provides a novel heterocyclic compound, a preparation method therefor, and a use thereof. The structure of the heterocyclic compound is as shown in formula (I). The co...
|
|
WO/2024/149270A1 |
The present invention belongs to the field of chemical drugs, and provides a 5-fluorouracil derivative and an anti-tumor use thereof. The structure of the 5-fluorouracil derivative is represented by formula (I). The compound provided by ...
|
|
WO/2024/083258A8 |
Disclosed in the present invention are a KRAS G12D degradation agent, and a preparation method and use therefor. The KRAS G12D degradation agent in the present invention is a compound as shown in formula I or I', and/or a stereoisomer, e...
|
|
WO/2024/151465A1 |
The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts X and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said c...
|
|
WO/2024/147009A1 |
One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, X is NH and Y is CO ring C is a 6-membered heteroaryl or aryl group, or a partially or fully unsaturated 6-member...
|
|
WO/2024/144215A1 |
The present invention relates to a novel compound and an organic electroluminescent device using same and, more specifically, to an organic compound having excellent electron transport ability, heat resistance, carrier transportability, ...
|
|
WO/2024/144192A1 |
The present invention relates to a novel organic light-emitting compound and an organic electroluminescent diode using same and, more specifically, to: a compound having excellent heat resistance, carrier transport ability, and light-emi...
|
|
WO/2024/140425A1 |
The present invention relates to a novel crystal form of aprocitentan (referred to as "compound I"), a preparation method therefor, a pharmaceutical composition containing the crystal form, and the use of the crystal form in the preparat...
|
|
WO/2024/141939A1 |
The present invention provides novel crystalline forms of Apabetalone or its hydrates or its solvates viz, crystalline propionic acid solvate of Apabetalone (Form APB-2), crystalline form of Apabetalone hydrate (Form APB-4), crystalline ...
|
|
WO/2024/141066A1 |
Disclosed in the present invention are compounds represented by formula (1), or tautomers, mesomers, racemates, enantiomers, diastereomers, mixture forms thereof, or pharmaceutically acceptable salts thereof. The compounds have excellent...
|
|
WO/2024/140595A1 |
Disclosed in the present invention are a tricyclic compound, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention is a compound as represented by formula (I) or a pharmaceutically acc...
|
|
WO/2024/144210A1 |
The present invention relates to a novel compound and to an organic electroluminescent device using same and, more specifically, to an organic compound having excellent electron transporting capability, heat resistance, carrier transport...
|
|
WO/2024/144246A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same, and, more specifically, to an organic compound having excellent electron transport ability, heat resistance, carrier transport...
|
|
WO/2024/145505A1 |
Pyrimidinyl compounds of formula I: (I), for use in methods of inhibiting Wee 1 A kinase.
|
|
WO/2024/144680A1 |
The invention relates to the compound shown in Formula I, II, III and IV or pharmaceutically acceptable salt, solvent, hydrate, hydrate salt, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer thereof effective in the ...
|
|
WO/2024/143336A1 |
In the present invention, a compound represent by formula Z-I has excellent bactericidal activity and has excellent stability. (In the formula: Q1 represents a phenyl group, or the like; Q2 represents a phenyl group, or the like; partial...
|
|
WO/2024/144213A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same and, more specifically, to: an organic compound which has excellent electron transport ability, heat resistance, carrier transp...
|
|
WO/2024/137981A1 |
Provided are compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, L, RB, Rc, n, and p are as defined herein. Also provided are pharmaceutically acceptable compositions comprising a compound of ...
|
|
WO/2024/130411A1 |
Inhibitors of the SARS-CoV-2 Mpro protease and methods of their use in treating a coronavirus infection in a subject are provided. The inhibitors may have the general structure (I) :
|
|
WO/2024/131742A1 |
A USP1-targeting small-molecule inhibitor and the use thereof. The present invention specifically relates to a compound of general formula (I), an enantiomer, a diastereomer, a tautomer, a salt, a crystal form, a solvate and/or an isotop...
|
|
WO/2024/136555A1 |
The present invention relates to: a novel compound which has excellent carrier transport ability, light emission ability, and thermal stability: and an organic electroluminescent device which comprises the compound in one or more organic...
|
|
WO/2024/131672A1 |
The present invention provides a compound of formula (I) having selective prostaglandin I2 receptor agonistic activity, and an isomer or pharmaceutically acceptable salt thereof, wherein each group is as defined in the description. The c...
|
|
WO/2024/130342A1 |
The present invention relates to compounds, pharmaceutical compositions of said compounds, and uses of said compounds, especially for inhibition of Transient Receptor Potential channel family, Vanilloid subfamily member 6 (TRPV6). The co...
|
|
WO/2024/131938A1 |
Provided in the present application are a quinazoline compound as represented by formula (I), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof, and pharmaceutical composition containing such quinazoline derivatives, w...
|
|
WO/2024/134368A1 |
The present invention relates to a solid-state form of Mavacamten, processes for preparing thereof and pharmaceutical composition thereof. In particular, the present invention relates to a crystalline MAV-2 of Mavacamten, the process and...
|
|
WO/2024/127343A1 |
The present invention discloses a novel type of highly potent ENPP-1 inhibitors for the treatment of various diseases particularly, cancer. The compounds of the invention have tail, core, and zinc binding portions (ZBP), where the key fe...
|
|
WO/2024/124357A1 |
A method of determining a risk of developing a neurological disorder in a Long-COVID patient comprising: (a) testing levels of at least one marker associated with a neurologic disorder in a sample taken from the Long-COVID patient, and (...
|
|
WO/2024/124287A1 |
The present invention relates generally to a compound and/or a composition comprising the compound, useful for the treatment of, or prevention of, a Coronavirus (CoV) infection in particular SARS-CoV/SARS-CoV-1 or SARS-CoV-2.
|
|
WO/2024/123038A1 |
The objective of the present invention is to provide a novel 2-((trans-4-(4-aryloxy)cyclohexyl)amino)quinazolinone derivative which exhibits anti-cancer activity through eIF2α phosphorylation efficacy. The novel synthesized derivative e...
|
|
WO/2024/122961A1 |
The objective of the present invention is to provide a novel 2-((trans-4-(4-aryloxy)cyclohexyl)amino)quinazolinone derivative which exhibits anti-cancer activity through eIF2α phosphorylation efficacy. The novel synthesized derivative e...
|
|
WO/2024/121048A1 |
The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2/7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particular...
|
|
WO/2024/121046A1 |
The present invention relates to compounds of formula (I) as defined in the specification capable of promoting the opening of Kv7.2/Kv7.3 potassium channels, a pharmaceutical composition comprising them, and their use as a drug, particul...
|
|
WO/2024/123717A1 |
Disclosed herein are compounds comprising a phenyl, pyridine, or pyrimidine core and pharmaceutically acceptable salts thereof, and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with ex...
|
|
WO/2024/123585A1 |
Provided are novel Substituted Quinazoline Derivative of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and X are as defined herein, as well as compositions comprising at least one Substituted Quinazoline...
|
|
WO/2024/118070A1 |
The present disclosure provides crystalline forms of the compound having Formula (I), wherein the crystalline forms are crystalline Forms A to U. The crystalline Forms A to U are characterized by an X-ray powder diffraction (XRPD) patter...
|
|
WO/2024/115549A1 |
The present invention relates to compounds of Formula (I), their synthesis and use as CCR8 receptor modulators in medicine.
|
|
WO/2024/114531A1 |
The present application relates to the field of medicine, and particularly relates to a drug linker compound. The drug may comprise a DNA topoisomerase inhibitor. A conjugate prepared from the drug linker compound, such as an antibody dr...
|
|
WO/2024/115673A1 |
The present invention relates to novel 3-Phenylquinazolinones in particular for the use in the treatment of cancer.
|
|
WO/2024/117859A1 |
The present invention relates to a novel organic compound and an organic electroluminescent device using same and, more specifically, to an organic compound having excellent heat resistance, carrier transport ability, light emission capa...
|
|
WO/2024/118830A1 |
Disclosed herein are atropisomers of Formula (I) that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are methods of isolating the atropisomers, pharmaceutical compositions comprising such compounds/compositions,...
|
|
WO/2024/116069A1 |
Aspects of the present disclosure provide novel intermediates that may be used for synthesis of Trilaciclib, pharmaceutically acceptable salts or derivatives thereof. Aspects of the present disclosure also relate to a method for preparat...
|
|
WO/2024/112731A1 |
Flavone, quinolinone, quinazolinone, and aurone derivatives are disclosed. The compounds have a structure according to formula I or formula II, or a pharmaceutically acceptable salt, hydrate, stereoisomer, or tautomer thereof. The compou...
|
|
WO/2024/109233A1 |
Provided in the present disclosure are a pyrimidoaromatic compound with a structure as shown in formula I', and a preparation method therefor and the use thereof. The compound has a significant inhibitory effect on the activities of KRAS...
|
|
WO/2024/110381A1 |
It is provided an ionizable lipid of formula (I) or a pharmaceutically acceptable salt thereof, or a stereoisomer of any one of them; a lipid nanoparticle comprising the ionizable lipid, particularly, as an encapsulation agent, optionall...
|
|
WO/2024/104464A1 |
The present invention provides a compound represented by formula (I), and a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt or prodrug thereof. The compound has a good Nav1.8 inhibitory effect.
|
